CN105796746B - Traditional Chinese medicine for preventing and treating recurrent upper respiratory tract infection - Google Patents
Traditional Chinese medicine for preventing and treating recurrent upper respiratory tract infection Download PDFInfo
- Publication number
- CN105796746B CN105796746B CN201610385997.6A CN201610385997A CN105796746B CN 105796746 B CN105796746 B CN 105796746B CN 201610385997 A CN201610385997 A CN 201610385997A CN 105796746 B CN105796746 B CN 105796746B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- upper respiratory
- respiratory tract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 88
- 206010046306 Upper respiratory tract infection Diseases 0.000 title claims abstract description 51
- 206010057190 Respiratory tract infections Diseases 0.000 title claims abstract description 48
- 230000000306 recurrent effect Effects 0.000 title claims description 20
- 229940079593 drug Drugs 0.000 claims abstract description 17
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 16
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 16
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 15
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 15
- 235000008434 ginseng Nutrition 0.000 claims abstract description 15
- 241000195955 Equisetum hyemale Species 0.000 claims abstract description 14
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 13
- 235000011477 liquorice Nutrition 0.000 claims abstract description 13
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 8
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 241000208340 Araliaceae Species 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 10
- 239000006187 pill Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 6
- 241000202726 Bupleurum Species 0.000 claims description 5
- 235000002226 Ranunculus ficaria Nutrition 0.000 claims description 5
- 241000207929 Scutellaria Species 0.000 claims description 4
- 238000007796 conventional method Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 2
- 241001530126 Scrophularia Species 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 35
- 230000008901 benefit Effects 0.000 abstract description 10
- 239000002994 raw material Substances 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 description 26
- 201000010099 disease Diseases 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 208000024891 symptom Diseases 0.000 description 12
- 206010037660 Pyrexia Diseases 0.000 description 11
- 230000001154 acute effect Effects 0.000 description 11
- 230000036039 immunity Effects 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 8
- 238000005728 strengthening Methods 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 210000003800 pharynx Anatomy 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 208000035143 Bacterial infection Diseases 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 6
- 206010068319 Oropharyngeal pain Diseases 0.000 description 6
- 201000007100 Pharyngitis Diseases 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 208000022362 bacterial infectious disease Diseases 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 208000035240 Disease Resistance Diseases 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 230000036737 immune function Effects 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 241000709661 Enterovirus Species 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 201000009240 nasopharyngitis Diseases 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000709687 Coxsackievirus Species 0.000 description 3
- 235000017443 Hedysarum boreale Nutrition 0.000 description 3
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 3
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 3
- 244000081426 Ranunculus ficaria Species 0.000 description 3
- 241000725643 Respiratory syncytial virus Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001174 ascending effect Effects 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 238000002636 symptomatic treatment Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 244000236521 Bupleurum rotundifolium Species 0.000 description 2
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 206010013952 Dysphonia Diseases 0.000 description 2
- 241001466953 Echovirus Species 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 208000010473 Hoarseness Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010023880 Laryngitis viral Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 206010047473 Viral pharyngitis Diseases 0.000 description 2
- 230000001760 anti-analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
- 229960004099 azithromycin Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 2
- 229960003408 cefazolin sodium Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 230000000312 effect on influenza Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 201000008195 viral laryngitis Diseases 0.000 description 2
- BITDLWAQPKSXTF-UHFFFAOYSA-M 1-[(3-nitrophenyl)methoxymethyl]pyridin-1-ium;chloride Chemical compound [Cl-].[O-][N+](=O)C1=CC=CC(COC[N+]=2C=CC=CC=2)=C1 BITDLWAQPKSXTF-UHFFFAOYSA-M 0.000 description 1
- CFJMRBQWBDQYMK-UHFFFAOYSA-N 1-phenyl-1-cyclopentanecarboxylic acid 2-[2-(diethylamino)ethoxy]ethyl ester Chemical compound C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 CFJMRBQWBDQYMK-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 201000006219 Herpangina Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037508 Punctate keratitis Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- -1 cefazolin sodium Chemical class 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000001847 jaw Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229960002581 moroxydine hydrochloride Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 230000017111 nuclear migration Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960003436 pentoxyverine Drugs 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 210000001584 soft palate Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002396 uvula Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000009571 yupingfeng Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine for preventing and treating repeated upper respiratory tract infection, which can effectively solve the problem of medication for preventing and treating repeated upper respiratory tract infection and adopts the technical scheme that the traditional Chinese medicine is calculated by the following weight fractions: 6-30 parts of radix bupleuri, 6-30 parts of scutellaria baicalensis, 6-30 parts of radix scrophulariae, 6-20 parts of scouring rush, 4-15 parts of sun-dried ginseng and 4-30 parts of liquorice; the invention has the advantages of rich raw materials, low cost, easy production, convenient taking and good effect, is an innovation of the medicine for treating the repeated upper respiratory tract infection and has obvious economic and social benefits.
Description
Technical Field
The invention relates to a medicine, in particular to a traditional Chinese medicine for preventing and treating repeated upper respiratory tract infection.
Background
Recurrent upper respiratory tract infections, also known as habitual cold. The upper respiratory tract infection is one of the most common clinical respiratory diseases, the incidence rate is high, generally, the upper respiratory tract infection occurs 2 to 4 times per year for adults, the incidence rate is higher for children, 6 to 8 times per year, and the disease can be developed all year round, and more diseases are developed in winter and spring. Repeated upper respiratory tract infection is frequently caused by children, old people, climacteric people and middle-aged and young patients with poor constitution and insufficient disease resistance.
The occurrence reasons of the repeated upper respiratory tract infection are consistent with the upper respiratory tract infection, except that the disease usually occurs repeatedly and is lingering and difficult to cure. Modern medicine considers that the cause of the disease is mainly two factors, namely exogenous factors. Mainly associated with viral and bacterial infections; approximately 70% to 80% of upper respiratory infections are caused by viruses. Including rhinoviruses, coronaviruses, adenoviruses, influenza and parainfluenza viruses, respiratory syncytial viruses, echoviruses, coxsackie viruses, and the like. In addition, about 20% to 30% of upper respiratory tract infections are caused by bacteria. Bacterial infections may be either direct or secondary to viral infections, with hemolytic streptococci being the most common, followed by haemophilus influenzae, pneumococcus, staphylococci, etc., and gram-negative bacteria occasionally. The first is body factor, which is mainly related to the low immune function and insufficient disease resistance of the body. Various causes of the decrease of the defense function of the whole body or the local respiratory tract, such as catching cold, rain, climate mutation, and fatigue, can cause the rapid propagation of viruses or bacteria existing in the upper respiratory tract or invading from the outside, thereby inducing the disease. The old and the young are weak, and patients with low immune function or chronic respiratory diseases are very easy to feel the disease.
The disease clinically comprises five types, namely ① common cold, commonly known as 'cold', also known as acute rhinitis or upper respiratory catarrh, which is caused by rhinovirus, coronavirus, parainfluenza virus, respiratory syncytial virus, echovirus, coxsackie virus and the like, ② acute viral pharyngitis or laryngitis, ③ acute herpetic angina, which is caused by rhinovirus, adenovirus, influenza A virus, influenza virus, parainfluenza virus, enterovirus, respiratory syncytial virus and the like, ④ pinoconjunctival fever, which is caused by adenovirus, coxsackie virus and the like, ⑤ bacterial pharynx-tonsillitis, which is caused by hemolytic streptococcus, haemophilus influenzae, pneumococcus, staphylococcus and the like.
The modern medicine mainly treats the disease through symptomatic treatment, no definite and effective method and medicine exist for the treatment of the pathogenic factors, the symptomatic treatment comprises ① antipyretic analgesia and mainly aims at fever symptoms, such as compound aspirin, acetaminophen, indometacin, pain-relieving tablets, ibuprofen and the like, ② decongestant mainly aims at pharyngeal congestion pain symptoms and uses pseudoephedrine hydrochloride, ③ antihistamine mainly aims at respiratory catarrhal symptoms, such as chlorpheniramine maleate or diphenhydramine, ④ antitussive mainly aims at cough symptoms and uses dextromethorphan, pentoxyverine and the like, the pathogeny treatment comprises ① antibacterial medicine treatment and treatment of bacterial infection or virus infection combined bacterial infection infected person, penicillin, a first generation cephalosporin such as cefazolin sodium, a macrolide such as azithromycin, ② antiviral medicine treatment, no antiviral medicine exists at present, broad-spectrum antiviral medicine such as ribavirin, moroxydine hydrochloride and the like is mainly used for treating bacterial infection or virus infection combined bacterial infection, the medicines such as cefazolin sodium cefazolin, a macrolide such as azithromycin, a ②, the antiviral medicine mainly has a certain effect on influenza virus, a certain effect on influenza virus inhibition effect, a traditional Chinese medicine for clinical treatment, a traditional Chinese medicine for oral medicine for treating influenza, a traditional Chinese medicine for reducing fever, a traditional Chinese medicine for treating influenza, a traditional Chinese medicine for treating, a traditional Chinese medicine for reducing fever symptoms, a traditional Chinese medicine for treating pathogen, a traditional Chinese medicine for treating influenza, a traditional Chinese medicine for reducing fever, a traditional Chinese medicine for treating.
Clinically, if a patient does not have basic diseases or complications, the acute upper respiratory infection can be completely relieved mostly through symptomatic treatment, etiological treatment and traditional Chinese medicine treatment. However, for recurrent upper respiratory tract infection, antiviral drugs and most of traditional Chinese medicines are basically ineffective, patients often fail to recover the disease, and the next cold recurs, which causes serious influence on the daily life of the majority of patients. For patients who frequently and repeatedly suffer from the disease and patients with low immunity, modern medicine mainly applies immunopotentiator therapy as appropriate, but no vaccine aiming at other viruses except influenza viruses is available at present. From the clinical point of traditional Chinese medicine at present, the traditional Chinese medicine mainly adopts the Yupingfeng powder to treat recurrent upper respiratory tract infection so as to strengthen and protect the exterior of the body, but is clinically suitable for patients with insufficient defensive qi, and has general effects on other symptoms. The disease is repeatedly attacked, so the health of the masses of people is seriously harmed, and the traditional Chinese medicines lack effective treatment means and methods.
Disclosure of Invention
In view of the above situation, the present invention aims to provide a Chinese medicine for preventing and treating recurrent upper respiratory tract infection, which can effectively solve the problem of medication for preventing and treating recurrent upper respiratory tract infection.
The technical scheme for solving the problem is that the traditional Chinese medicine is prepared from the following components in parts by weight: 6-30 parts of radix bupleuri, 6-30 parts of scutellaria baicalensis, 6-30 parts of radix scrophulariae, 6-20 parts of scouring rush, 4-15 parts of sun-dried ginseng and 4-30 parts of liquorice;
the traditional Chinese medicine is decoction, oral liquid, water pill, capsule and granule.
The invention has the advantages of rich raw materials, low cost, easy production, convenient taking and good effect, is an innovation of the medicine for treating the repeated upper respiratory tract infection and has obvious economic and social benefits.
Detailed Description
The following examples are provided to explain the present invention in detail.
Example 1
In the specific implementation of the invention, the traditional Chinese medicine is calculated by the following weight fractions: 6-30 parts of radix bupleuri, 6-30 parts of scutellaria baicalensis, 6-30 parts of radix scrophulariae, 6-20 parts of scouring rush, 4-15 parts of sun-dried ginseng and 4-30 parts of liquorice, and each water pill or capsule is equivalent to 0.5g of crude drug;
the traditional Chinese medicine composition can be prepared into granules according to a conventional method and packaged, and each bag is equivalent to 3g of crude drug;
the Chinese medicinal composition can also be made into oral liquid by conventional method, and each 10ml of oral liquid contains 3g of crude drug.
Example 2
In the specific implementation of the invention, the traditional Chinese medicine is calculated by the following weight fractions: 10-20 parts of radix bupleuri, 10-20 parts of radix scutellariae, 10-20 parts of radix scrophulariae, 10-15 parts of scouring rush, 5-10 parts of sun-dried ginseng and 10-25 parts of liquorice are prepared into decoction, the method is that the components are mixed together, water with the weight 8-10 times of the sum of the weight of the components is added into the mixture every time, the mixture is decocted for 2 times, water is added into the mixture for the first time, the mixture is soaked for 40-60 minutes, the mixture is decocted by strong fire first, then decocted by slow fire for 30-40 minutes, and filtered to obtain first filtrate; decocting with strong fire after adding water for the second time, decocting with slow fire for 30-40 min, filtering to obtain second filtrate, mixing the filtrates, and mixing to obtain decoction.
Example 3
In the specific implementation of the invention, the traditional Chinese medicine can also be calculated by the following weight fractions: 8-15 parts of bupleurum, 20-28 parts of scutellaria, 8-15 parts of figwort, 15-18 parts of scouring rush, 5-9 parts of sun-dried ginseng and 18-28 parts of liquorice.
Example 4
In the specific implementation of the invention, the traditional Chinese medicine can also be calculated by the following weight fractions: 20-28 parts of radix bupleuri, 8-15 parts of scutellaria baicalensis, 20-28 parts of radix scrophulariae, 8-12 parts of scouring rush, 11-14 parts of sun-dried ginseng and 5-15 parts of liquorice.
Example 5
In the specific implementation of the invention, the traditional Chinese medicine can also be calculated by the following weight fractions: 18 parts of bupleurum, 18 parts of scutellaria, 18 parts of figwort, 13 parts of scouring rush, 10 parts of sun-dried ginseng and 17 parts of liquorice.
The invention is based on the theory of traditional Chinese medicine, according to the compatibility principle of traditional Chinese medicines and the pathogenesis of repeated upper respiratory tract infection, adopts the unique scheme of 'harmonizing shaoyang, dispelling wind and clearing heat, strengthening body resistance to achieve pathogenic factors and regulating immunity' as main treatment for treating repeated upper respiratory tract infection through scientific research, experiment and practice summary. The treatment medication method mainly takes decoction as the main part in the acute stage and takes oral liquid, pills, capsules and granules as the main part in the remission stage, and effectively solves the problem of repeated attack of the disease. In clinical prevention and treatment of diseases with repeated upper respiratory tract infection, the causes of most patients are that pathogenic factors attack shaoyang in traditional Chinese medicine, the pivot is unfavorable, and healthy qi is insufficient and cannot expel pathogenic factors out. The deficiency of healthy qi cannot expel pathogenic factors out in time, and pathogenic factors struggle orthogonally with shaoyang, so that the pivot cannot operate, and if the immune function is low for a long time, the upper respiratory tract infection attacks repeatedly, thus forming the disease. Through a great deal of clinical exploration and summarization, the view points of ' generating qi by lack of fire ' and ' governing the body ' by lack of yang ' of the classic theory of traditional Chinese medicine are combined, and the treatment medicine for ' harmonizing shaoyang, dispelling wind and clearing heat, strengthening body resistance to achieve pathogenic factors and regulating immunity ' is developed. The medicine uses radix bupleuri to relieve exogenous pathogenic factors of shaoyang, radix Scutellariae to relieve endogenous pathogenic factors of shaoyang, radix scrophulariae to clear heat and nourish yin, cool blood and relieve sore throat, herba Equiseti hiemalis to disperse wind-heat, radix Ginseng to support shaoyang healthy qi, and radix Glycyrrhizae Preparata to strengthen middle warmer and harmonize medicine property. The medicines are matched to achieve the effects of harmonizing shaoyang, dispelling wind, clearing heat, strengthening body resistance to eliminate pathogenic factors and regulating immunity, thereby enhancing the disease resistance of organisms and curing diseases.
In the pharmaceutical composition of the present invention, wherein:
bupleurum root: bitter and pungent in flavor, slightly cold in nature, entering liver and gallbladder meridians, ascending mainly; it has the effects of dispelling pathogenic wind, relieving fever, dispersing stagnated liver qi, relieving qi stagnation, and invigorating yang. The main ingredient of the recipe is thin qi ascending and mainly ascending, which can induce the clear yang to ascend and disperse stagnation, and fragrant and smooth flow of qi, which is good at dispelling wind and heat to permeate yang qi and induce the pathogen of shaoyang to go out and resolve. The formula has the effects of dispelling wind and clearing heat, and removing heat and pungent and mild effects, and can induce the qi of clear yang to ascend so as to dispel wind and eliminate pathogenic factors and remove pathogenic heat, so that the formula has good effects of dispelling wind and clearing heat for treating diseases such as alternating cold and heat, cold and fever, and the like.
Scutellaria baicalensis: bitter taste and cold nature, entering heart, lung, stomach, gallbladder and large intestine meridians, it has the actions of clearing heat and drying dampness, purging fire and removing toxicity, stopping bleeding and preventing abortion, so it is good at clearing lung fire and the excess heat of middle-upper energizer. In the recipe, Huangqin is bitter in flavor and can descend and clear away the pathogenic factors of shaoyang interior. Because it enters Shaoyang gallbladder meridian, it is combined with chai Hu to resolve the pathogen of Shaoyang and treat the syndrome of wind-heat of Shaoyang with pathogen in the half exterior and half interior. In the formula, the Chinese thorowax root is matched with the Chinese thorowax root, and is used for clearing and relieving hair in the middle to harmonize Shaoyang pivot; in addition, it has strong actions of purging fire and removing toxicity, so it can be indicated for swollen and sore throat.
Figwort root: sweet, bitter, salty and cold in nature, entering lung, stomach and kidney meridians. Has effects in clearing away heat, cooling blood, nourishing yin, and removing toxic substances. It is salty and cold, and has the actions of clearing heat and purging fire, cooling blood and removing toxicity, softening hardness and dissipating nodulation, relieving sore throat and alleviating swelling. It is indicated for swelling and pain of throat due to exogenous pathogenic toxin and excessive heat-toxin, and also for swelling and pain of throat due to yin deficiency with effulgent fire. In the recipe, yin is nourishing and toxicity is removing, and sweet and cold are clearing and relieving, the recipe is mainly used for treating sore throat.
Scouring rush: sweet and bitter in flavor, neutral in nature, entering lung and liver meridians. It can disperse wind-heat, improve eyesight, remove nebula, induce sweating and release exterior, and is mainly indicated for diseases such as wind-heat and conjunctival congestion. In the recipe, the actions of chai Hu and Huang Qin to disperse wind-heat are enhanced.
Sun-dried ginseng: sweet and slightly bitter in flavor, slightly warm in nature, entering lung and spleen meridians. The product has effects of invigorating primordial qi, invigorating spleen, benefiting lung, promoting fluid production, quenching thirst, tranquilizing mind, and improving intelligence. It is mainly used for the treatment of deficiency of five viscera, such as primordial qi deficiency, spleen and stomach weakness, lung deficiency, short breath and debilitation. Because it tonifies five zang organs, calms spirit, calms soul, and eliminates pathogenic qi, it can tonify primordial qi, strengthen healthy qi to eliminate pathogenic qi, and it is indicated for all syndromes of internal injury and external infection due to insufficiency of healthy qi or deficiency of healthy qi due to incomplete pathogenic qi. For instance, it is used for external contraction due to deficiency, it is usually indicated for tonifying qi and relieving exterior syndrome. In the recipe, it is combined with gan Cao to strengthen healthy qi and expel pathogens, and it has the actions of regulating and enhancing immunity.
Licorice root: sweet and mild in flavor, and enters heart, lung, spleen and stomach meridians; the product has the effects of invigorating qi, strengthening middle-jiao, moistening lung, arresting cough, clearing away heat and toxic materials, relieving spasm and pain, and harmonizing the drugs. The honey-fried licorice root has the effects of tonifying spleen and qi and protecting the middle warmer; the raw licorice root has good effects of clearing away heat and toxic materials, eliminating phlegm and relieving cough. Can be used for treating weakness of spleen and stomach, asthenia, palpitation, short breath, cough, spasm and pain of abdomen and limbs, carbuncle, swelling, and sore, and relieving toxicity and strong property of the medicine.
The medicines are matched to achieve the effects of harmonizing shaoyang, dispelling wind and clearing heat, strengthening body resistance to achieve evil and regulating immunity, so that the traditional Chinese medicine is used for regulating and preventing recurrent acute upper respiratory tract infection. Through clinical practical application, the method obtains very satisfactory beneficial technical effects, and the related data are as follows:
the diagnosis is made according to the national standards of the health and birth control committee industry, namely ' diagnosis and treatment of acute upper respiratory tract infection ' and ' the pediatric division of the Chinese medical science ' standard of ' traditional Chinese medical guideline for treating recurrent respiratory tract infection of children ' (traditional Chinese medical journal of 2008, 11 month, 4 th volume, 6 th) ', and the standards are as follows:
diagnostic criteria for acute upper respiratory infection:
1. there is a history of catching cold and tiredness.
2. Typing diagnosis
1) Common cold: the acute onset of the disease has the symptoms of sneezing, nasal obstruction, watery nasal discharge, dry and itchy pharynx, burning sensation or pharyngalgia, hoarseness or cough and mild general symptoms. The nasal mucosa is detected to be congested and edematous, and has more secretion and mild congestion of the pharynx.
2) Acute viral pharyngitis or laryngitis: pharyngalgia, hoarseness, mild dry cough, fever, general soreness and discomfort. Inspection shows pharyngeal congestion with gray-white punctate exudate, hyperplastic lymph follicles in the posterior pharyngeal wall, and enlargement of submandibular lymph nodes.
3) Herpangina: obvious sore throat and fever. Inspection of the throat congestion, gray and hilly herpes and superficial ulcer on the surface of the soft palate, uvula, pharynx and tonsil.
4) Heat of the pharynx conjunctiva: lacrimation, redness of the eye, sore throat, fever, general debilitation, and eye follicular conjunctivitis, transient superficial punctate keratitis, corneal upper and lower subcutaneous opacification, and swelling of the anterior auricular lymph nodes.
5) Bacterial amygdalitis pharyngolaryngitis: acute onset, obvious pharyngalgia, aversion to cold, fever, headache and general malaise; inspection of the pharyngeal portion for obvious congestion, swelling of tonsils, congestion, yellowish white punctate exudates on the surface, swelling of jaw lymph nodes, and tenderness.
3. The conventional white blood cells in blood are normal or low, and the proportion of lymphocytes is increased. Or leukocytosis and neutrophilia and nuclear migration.
4. Acute infectious diseases were excluded.
The selection criteria of cases are ① meeting the diagnosis criteria of acute upper respiratory tract infection, ② repeated upper respiratory tract infection attacks more than 6 times per year, or repeated attacks more than 6 times within 6 months, and the interval between two infections is more than 7 days.
The treatment scheme comprises the following steps:
patients diagnosed with recurrent upper respiratory infections were treated with the traditional Chinese medicine of the invention:
1. repeated administration method of the medicine in the attack stage of upper respiratory tract infection for treating clinical morbidity
The decoction is taken 3 times each time, once in the morning, at noon and evening, and 200 ml each time. One treatment course lasts for 3 days, and the curative effect is counted in 2 treatment courses.
When the water pill or capsule is taken, each water pill or capsule contains 0.5g of effective component, 3 times daily, 6-8 capsules each time. When the granule is prepared, each bag of the granule contains 3g of effective components, 3 times a day, and 2-4 bags each time. When the oral liquid is prepared, 10ml of liquid medicine of each oral liquid contains 3g of active ingredients, 3 times a day, and 2-4 pieces of the liquid medicine are prepared each time. One treatment course lasts for 3 days, and the curative effect is counted in 2 treatment courses.
2. The preparation can be taken at ordinary times for regulating immunity and preventing diseases
Oral liquid, watered pill, capsule or granule can be administered. When the raw material medicines are prepared into water pills or capsules, each water pill or capsule contains 0.5g of active ingredients, 3 times a day, and 6-8 capsules each time. When the granule is prepared, each bag of the granule contains 3g of effective components, 3 times a day, and 2-4 bags each time. When the oral liquid is prepared, 10ml of liquid medicine of each oral liquid contains 3g of active ingredients, 3 times a day, and 2-4 pieces of the liquid medicine are prepared each time. 60 days is a course of treatment, and the curative effect is counted in 3 courses of treatment.
The curative effect standard is as follows: made according to the ' guiding principle of new drug clinical research of traditional Chinese medicine (trial) 2002, Zhengxian cornus ' major edition '.
1. Therapeutic standard of acute upper respiratory infection
1) And (3) healing: the body temperature returns to normal within 3 days after treatment, and the symptoms of upper respiratory tract infection disappear completely.
2) The effect is shown: the body temperature is normal within 3 days of treatment, and the symptoms of upper respiratory infection mostly disappear.
3) The method has the following advantages: the body temperature is reduced within 3 days of treatment compared with the prior treatment, and the main symptoms of the upper respiratory tract infection are partially disappeared.
4) And (4) invalidation: the body temperature is not reduced or increased within 3 days of treatment, and the main symptoms of upper respiratory tract infection are not improved.
2. Repeated upper respiratory tract infection therapeutic standard
1) And (3) healing: after 120 days of treatment, the upper respiratory tract infection attacks 1-2 times per year.
2) The effect is shown: after 120 days of treatment, the upper respiratory tract infection attacks 3-4 times per year.
3) The method has the following advantages: after 180 days of treatment, the upper respiratory tract infection attacks 5-6 times per year.
4) And (4) invalidation: after 180 days of treatment, the upper respiratory tract infection attacks 6 times or more per year.
Statistical treatment
The traditional Chinese medicine is taken according to the treatment scheme, 124 cases of repeated upper respiratory tract infection, 64 cases of men and 60 cases of women are treated in 2008-2016, and the proportion of the cases to the cases is 1.07: 1, patients are between 4-65 years old, wherein 72 children are 4-14 years old, 24 middle-aged and elderly people are 55 years old, 28 children are 15-54 years old, the average age is 13.7 years old, the course is 6-24 months, and the average course is 9 months.
Among 124 patients, 112 patients were cured, accounting for 90.3%; 8 cases of obvious effect account for 6.5 percent; ineffective 4 cases account for 3.2%; the total effective rate is 96.8%.
For 58 patients with recurrent upper respiratory tract infection in the attack stage, 30 men and 28 women in the patients with recurrent upper respiratory tract infection have symptoms relieved or relieved to different degrees after taking the decoction for 3 days, the effective rate is almost 100 percent, and no adverse reaction is found in the taking period, which shows that the curative effect is stable and reliable, and the medication is safe.
Conclusion
The research results show that the invention can reduce the number of times of foot adding and the number of times of body twisting of an inflammation and pain model mouse, and increase the contents of IL-1 β and PGE2 in the serum of the inflammation and pain model mouse, thereby showing that the invention has stronger anti-inflammatory and analgesic effects, the anti-inflammatory and analgesic effects are realized by adjusting the immunologic function of the organism, and the clinical practical application proves that the invention has very good effects, has the effects of relieving the Yang, dispelling wind and clearing heat, strengthening the body resistance to pathogenic factors and adjusting the immunity, and the medicines are matched to achieve the effects of relieving the Yang, dispelling the wind and clearing heat, strengthening the body resistance to pathogenic factors and adjusting the immunity to enhance the disease resistance of the organism, so that the disease is cured, the invention can be effectively used for the regulation and prevention of the recurrent acute upper respiratory tract infection, has stable and reliable curative effect and safe medication, and compared with the prior art, has the following outstanding positive and beneficial technical effects:
(1) according to the traditional Chinese medicine theory and the long-term clinical practice of the inventor, the invention forms a unique treatment scheme which mainly aims at harmonizing shaoyang, dispelling wind and clearing heat, strengthening body resistance to pathogenic factors and regulating immunity. The medicine has the advantages of reasonable compatibility of raw materials, complementary efficacy and good synergistic effect. Clinical application and experimental research show that the medicament can treat both principal and secondary aspect of disease for patients with recurrent acute upper respiratory tract infection which belongs to deficiency of vital qi and invasion of exogenous pathogenic factors, the curative effect is consolidated after healing, and the total effective rate can reach 96.8%.
(2) The invention is a pure traditional Chinese medicine product, and has the advantages of safety, quick response and good treatment effect. Generally, the traditional Chinese medicine takes effect in 1-2 courses of treatment in the acute infection period, can obviously improve the physique of a patient, enhance the disease resistance and improve the immune function after being taken for 1-3 courses of treatment at ordinary times, and has a prevention effect on recurrent acute upper respiratory tract infection. The traditional Chinese medicine composition has the advantages of small dosage for patients, no drug resistance, no toxic or side effect, easy acceptance by the patients, avoidance of toxic or side effect caused by large-dose western medicine, practical application value and remarkable economic and social benefits.
Claims (6)
1. A traditional Chinese medicine for preventing and treating recurrent upper respiratory tract infection is characterized by comprising the following components in parts by weight: 6-30 parts of radix bupleuri, 6-30 parts of scutellaria baicalensis, 6-30 parts of radix scrophulariae, 6-20 parts of scouring rush, 4-15 parts of sun-dried ginseng and 4-30 parts of liquorice;
the traditional Chinese medicine is decoction, oral liquid, water pill, capsule or granule.
2. The traditional Chinese medicine for preventing and treating recurrent upper respiratory tract infection according to claim 1, which is characterized by comprising the following components in parts by weight: 6-30 parts of radix bupleuri, 6-30 parts of scutellaria baicalensis, 6-30 parts of radix scrophulariae, 6-20 parts of scouring rush, 4-15 parts of sun-dried ginseng and 4-30 parts of liquorice, and each water pill or capsule is equivalent to 0.5g of crude drug;
the traditional Chinese medicine composition can be prepared into granules according to a conventional method and packaged, and each bag is equivalent to 3g of crude drug;
the Chinese medicinal composition can also be made into oral liquid by conventional method, and each 10ml of oral liquid contains 3g of crude drug.
3. The traditional Chinese medicine for preventing and treating recurrent upper respiratory tract infection according to claim 1, which is characterized by comprising the following components in parts by weight: 10-20 parts of radix bupleuri, 10-20 parts of radix scutellariae, 10-20 parts of radix scrophulariae, 10-15 parts of scouring rush, 5-10 parts of sun-dried ginseng and 10-25 parts of liquorice are prepared into decoction, the method is that the components are mixed together, water with the weight 8-10 times of the sum of the weight of the components is added into the mixture every time, the mixture is decocted for 2 times, water is added into the mixture for the first time, the mixture is soaked for 40-60 minutes, the mixture is decocted by strong fire first, then decocted by slow fire for 30-40 minutes, and filtered to obtain first filtrate; decocting with strong fire after adding water for the second time, decocting with slow fire for 30-40 min, filtering to obtain second filtrate, mixing the filtrates, and mixing to obtain decoction.
4. The traditional Chinese medicine for preventing and treating recurrent upper respiratory tract infection according to claim 1, which is characterized by comprising the following components in parts by weight: 8-15 parts of bupleurum, 20-28 parts of scutellaria, 8-15 parts of figwort, 15-18 parts of scouring rush, 5-9 parts of sun-dried ginseng and 18-28 parts of liquorice.
5. The traditional Chinese medicine for preventing and treating recurrent upper respiratory tract infection according to claim 1, which is characterized by comprising the following components in parts by weight: 20-28 parts of radix bupleuri, 8-15 parts of scutellaria baicalensis, 20-28 parts of radix scrophulariae, 8-12 parts of scouring rush, 11-14 parts of sun-dried ginseng and 5-15 parts of liquorice.
6. The traditional Chinese medicine for preventing and treating recurrent upper respiratory tract infection according to claim 1, which is characterized by comprising the following components in parts by weight: 18 parts of bupleurum, 18 parts of scutellaria, 18 parts of figwort, 13 parts of scouring rush, 10 parts of sun-dried ginseng and 17 parts of liquorice.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610385997.6A CN105796746B (en) | 2016-06-03 | 2016-06-03 | Traditional Chinese medicine for preventing and treating recurrent upper respiratory tract infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610385997.6A CN105796746B (en) | 2016-06-03 | 2016-06-03 | Traditional Chinese medicine for preventing and treating recurrent upper respiratory tract infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105796746A CN105796746A (en) | 2016-07-27 |
| CN105796746B true CN105796746B (en) | 2020-04-10 |
Family
ID=56428237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610385997.6A Active CN105796746B (en) | 2016-06-03 | 2016-06-03 | Traditional Chinese medicine for preventing and treating recurrent upper respiratory tract infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105796746B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113616747B (en) * | 2021-05-20 | 2023-03-24 | 天津中医药大学 | Traditional Chinese medicine composition for healing infectious diseases and application thereof |
-
2016
- 2016-06-03 CN CN201610385997.6A patent/CN105796746B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| 《张锡纯擅用汗法治温病》;孙浩;《南京中医药大学学报》;20070531;第143和144页 * |
| 小柴胡汤治疗小儿反复上呼吸道感染30例;杨京华等;《浙江中医杂志》;20020625(第06期);第241页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105796746A (en) | 2016-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111671867B (en) | Novel traditional Chinese medicine composition for treating mild coronary virus pneumonia cough | |
| CN102091226A (en) | Chinese medicine composition for treating chronic pharyngitis | |
| CN102091250B (en) | Traditional Chinese medicine for treating acute tonsillitis | |
| CN104800714A (en) | Traditional Chinese medicine composition for treating chronic pharyngitis | |
| CN104983968B (en) | Antipyretic traditional Chinese medicine composition and preparation method thereof | |
| CN111840456A (en) | Chinese medicinal composition for treating respiratory system diseases | |
| CN105796746B (en) | Traditional Chinese medicine for preventing and treating recurrent upper respiratory tract infection | |
| CN104940691A (en) | Treatment medicine for novel bunyaviridae infection | |
| CN102526236B (en) | Pharmaceutical formulation for treating influenza and preparation method thereof | |
| CN104800655A (en) | Traditional Chinese medicine for treating infantile pneumonia | |
| CN113750188B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating cold | |
| CN104491825B (en) | A kind of Chinese medicine ointment for the treatment of oral ulcer | |
| CN102973753A (en) | Traditional Chinese medicine for treatment of chronic pharyngitis | |
| CN104606533A (en) | Traditional Chinese medicine decoction for treating pharyngitis | |
| CN105412877A (en) | Traditional Chinese medicine preparation for treating influenza and preparation method thereof | |
| CN104116960A (en) | Traditional Chinese medicinal preparation for treating hand-foot-and-mouth disease | |
| CN103623369B (en) | A kind of Chinese medicinal formulae for the treatment of tonsillitis, chronic pharyngitis | |
| CN108815329A (en) | A kind of Chinese medicine composition and preparation method thereof for treating flu | |
| CN105998608A (en) | Traditional Chinese medicine composition for treating rhinitis | |
| CN1234395C (en) | Medicinal tea of infused in boiling water and its production method | |
| CN104491391A (en) | Traditional Chinese medicine composition for treating pharyngitis | |
| CN106110244A (en) | Powder for relieving cough and asthma | |
| CN104998189A (en) | Traditional Chinese medicine powder for treating infantile oral ulcer of wind-heat spleen type and preparation method thereof | |
| CN112618631A (en) | A Chinese medicinal composition for treating oral ulcer and aphtha of the mouth and tongue, and its preparation method | |
| CN104189610A (en) | Traditional Chinese medicine composition for treating bronchitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |